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GFORCE-PD still going strong in 2016
Malin Parmar1, Jun Takahashi2, Lorenz Studer3 and Roger A Barker4
In 2014, a new initiative was undertaken by groups working on plans for the transplantation of stem-cell-based derived
dopaminergic neurons for treating Parkinson’s disease patients. This GForce-PD group held its annual meeting on 18–19 April 2016
in Chicago at Rush University to discuss their progress and the challenges that the translation of this experimental therapy still
faces. Over 2 days, the key issues were discussed around the cell lines that will be used, the differentiation protocols, preclinical
testing, GMP-adaptation, and cell manufacturing to allow ﬁrst in human clinical trials, which are anticipated to start in 2017–2018.
GForce-PD members also discussed how they can improve outreach and be of better service to the Parkinson's disease (PD)
community and help them to make the best possible decisions when pursuing stem cell treatments.
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INTRODUCTION
In 2014, a group of scientists and clinicians met for the ﬁrst time to
focus on accelerating the translation of stem-cell-based therapies
to the clinic for ﬁrst in human trials.1 The rationale for this was the
belief that collective work around developing the necessary
protocols to allow cells to get to patients would be facilitated
and enhanced by such a combined effort. In addition, a further
strength of the initiative would be to ensure that any such trial is
only undertaken when all the necessary elements are in place,
both in terms of regulatory approval and preclinical evidence of
graft survival, safety and efﬁcacy.2 The group that met in London
UK became known as GForce-PD and includes leading groups
from Europe funded by the EU, TransEuro (http://www.transeuro.
org.uk/) and NeuroStemCellRepair (http://www.neurostemcellre
pair.org/); the NYSTEM (New York State Stem Cell Science)
consortium led by Lorenz Studer and Viviane Tabar (https://
www.mskcc.org/research-areas/programs-centers/new-york-state-
stem-cell-science-consortia), and the CiRA group of Jun Takahashi
(https://www.cira.kyoto-u.ac.jp/e/research/takahashi_summary.html),
along with others linked to this work through their role in patient
organizations as well as relevant funding agencies. The second of
these meetings took place last year in New York at the Memorial
Sloan Kettering Cancer Center, and the most recent took place in
Chicago, hosted by Jeff Kordower on the 18–19 April.
At this latest meeting it was clear that great progress had been
made over the previous 12 months in terms of moving closer to
the clinic for a ﬁrst in human trial with stem-cell-derived
dopaminergic cells, as well as helping deﬁne the best way to
discriminate between therapies that are of merit versus those that
are not. This was illustrated by discussing the recently reported
planned trial using parthenogenetic embryonic stem cells for a
trial in 12 PD patients in Melbourne run by the company ISCO—a
commentary of which can be found in ref. 3.
Key points discussed:
1. The development of a stem-cell-based therapy for clinical
application is not straightforward, especially at the regulatory
level. This was well illustrated by the talk of Jane Lebkowski
from Asterias Biotherapeutics who led us through the long
route by which their stem-cell-derived neural progenitor
product was eventually taken to clinical trials in patients with
spinal cord injury.
2. TRANSEURO is an EU funded clinical trial looking at better
understanding how to optimize the transplantation of human
fetal ventral mesencephalic tissue into patients with PD. Roger
Barker summarized the program and the problems that have
arisen during its long evolution, as well as commenting that
11 transplants have now been successfully completed in the
last 11 months. The design of this trial has helped deﬁne the
tools needed for any stem cell studies in patients, and this was
discussed in terms of assessment tools, patient selection and
primary end points.
3. NeuroStemCellRepair is another EU consortium that has as
part of its remit to deliver a GMP compatible dopaminergic
cell derived from a stem cell source for use in patients with
PD. Malin Parmar described how the protocols have now been
modiﬁed to be of the necessary GMP standard, without them
compromising the differentiation efﬁciency and functional
efﬁcacy of the cells so produced.4,5 This work is expected to
lead to a ﬁling for a clinical trial in 2018.
4. Jun Takahashi also explained how their iPS programme for PD
has now been modiﬁed as part of the CiRA programme of work
on regenerative medicine. Their work showed how the protocol
for generating iPS-derived dopamine cells has improved in
terms of the efﬁcacy and authenticity of the cells they now are
testing in non-human primate xenografts.6 This will lead onto
trials in the near future using allogeneic (not autologous) iPS
cells as the donor source. In particular they plan to use so called
HLA-homozygous iPSCs, which provide a ‘hybrid’ between
personalized medicine and off-the-shelf therapies. It is antici-
pated that 75 lines will be needed to cover ~ 80% of the
Japanese population from this immunological perspective.
5. Lorenz Studer summarized the last 12 months of work that
his group has undertaken using the WA09/H9 ES cell line in
terms of modifying their differentiation protocol.7,8 They have
1Wallenberg Neuroscience Center, and Lund Stem Cell Center Lund University Lund, Sweden; 2Center for iPS Cell Research and Application (CiRA) Kyoto Univerisity Kyoto, Japan;
3Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Centre, New York, NY, USA and 4John van Geest Centre for Brain Repair, Department of Clinical Neuroscience,
University of Cambridge, Cambridge, UK.
Correspondence: RA Barker (rab46@cam.ac)
Received 5 May 2016; revised 23 May 2016; accepted 2 June 2016
www.nature.com/npjparkd
Published in partnership with the Parkinson's Disease Foundation
now locked down this protocol and started GMP production of
the cells. The team, sponsored by NYSTEM have a meeting
scheduled with the FDA in May 2016 to discuss the IND
enabling studies planned for their trial. They anticipate ﬁling for
a clinical trial to begin late in 2017.
6. In addition, a number of other presentations on stem cells
were given:
J Kwang Soo Kim (Harvard University) discussed his work on
iPS cell derivation and the processes limiting and controlling
reprogramming;9
J Ernest Arenas (Karolinska Institute) discussed his recent
ﬁndings on midbrain development in the mouse and human
using single-cell transcriptomics;10
J Tilo Kunath (Edinburgh University) presented his data on the
genetic stability of different ES cell lines,11 as well as ways to
optimize and monitor the dopaminergic differentiation
protocol.11
7. Other aspects of neural transplantation were discussed, includ-
ing Jeff Kordower’s presentation on some recent post mortem
ﬁndings in a patients grafted with fetal VM tissue as part of the
original NIH funded trials. Claire Henchcliffe, with the assistance
of Cyndy McRae, and the team at Weill Cornell Medical College,
was able to identify and meet with a number of patients who
had participated in these trials. She presented very long-term
follow-up data on their current clinical status and neuroimaging
ﬁndings almost 2 decades after their original fetal grafts.
8. Finally, a number of other key issues were discussed:
J Inmaculada de Melo-Martin (Weill Cornell Medical College)
presented a discussion on some of the major ethical issues
in trials of the type proposed, including the informed
consent process, crafting appropriate inclusion and exclu-
sion criteria for subject selection, and the need for long-term
follow-up;12
J Johann Thaheld discussed intellectual property and aspects
of commercialization that need to be considered, if any of
these therapies are to become mainline treatments for PD;
J Patrik Brundin (van Andel Institute) discussed the possible
role of GForce-PD in commenting on trials (both to the
scientiﬁc and patient community) that seem to pursue
practices that are different to those advocated in the
International Society for Stem Cell Research guidelines and
adopted and implemented by GForce-PD members. His
presentation spurred a discussion on how GForce-PD can
enhance interactions with the public and engage with the
patient community to connect, inform, and educate on the
importance of well-planned and scientiﬁcally sound clinical
trials using stem cells. Similarly, the group thought that
informing clinicians about the status of ongoing work is
necessary and relevant to their ability to counsel patients
and respond to potential inquiries about stem cell trials.
J And last, the group decided to nominate a steering
committee that will shape the future of this group, with
members chosen from each of the relevant parties that
currently make up GForce-PD.
Over a short one-and-a-half-day period all these various topics
were presented and vigorously discussed in a spirit of transpar-
ency, collaboration, and passion. Indeed, this meeting once more
encapsulated so much of what drives early-stage translational
medicine—namely the capacity to work together for the common
good by allowing open debate between those with expertize in
the basic science; clinical trials and practice; those knowledgeable
in regulatory oversight by national/international agencies; and
with attention to patient experiences and expectations. All of
which augurs well as we plan for the 4th Annual G FORCE-PD
meeting in 2017 to be held in Kyoto, Japan.
Finally, with the progress made by all teams in terms of GMP
adaptation and cell manufacturing, it is clear that stem-cell-based
therapies for PD are only very few years away from the ﬁrst clinical
trials. Although the route to the clinic can seem like a slow and
windy road, it is important to remember that the process by which
science becomes medicine should be designed to minimize
harm and maximize beneﬁt (ref http://www.closerlookatstemcells.
org/stem-cells-and-medicine/nine-things-to-know-about-stem-cell-
treatments). This is essential so as to ensure that the scientiﬁc,
clinical and patient community’s enthusiasm to harness the
promise of stem cell therapies, is tempered to avoid premature
clinical applications which has the potential to derail this whole
ﬁeld of regenerative medicine and place patients at risk.
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